

Supplemental Amendment
Docket No. 2625-E

Immunex Corporation

41. An antibody that specifically binds to a TRAIL-R polypeptide selected from the group consisting of:

a) amino acids x to 440 of SEQ ID NO:2, wherein x represents an integer from 51 through 59; and

b) a fragment of (a), wherein said fragment is capable of binding TRAIL, or an antigen-binding fragment of said antibody.

42. The antibody or antigen-binding fragment of claim 41 wherein the polypeptide consists essentially of amino acids x to 210 of SEQ ID NO:2.

43. An antibody that specifically binds to a TRAIL-R polypeptide selected from the group consisting of:

(a) a polypeptide that binds TRAIL and can be isolated from human cell membranes, wherein the TRAIL-R is characterized as comprising the amino acid sequence VPANEGD (amino acids 327-333 of SEQ ID NO:2); and

(b) a fragment of (a), wherein said fragment is capable of binding TRAIL, or an antigen-binding fragment of said antibody.

44. The antibody or antigen-binding fragment of claim 43 wherein said polypeptide is further characterized by a molecular weight of about 50 to 55 kilodaltons as determined by SDS-polyacrylamide gel electrophoresis.

45. The antibody or antigen-binding fragment of claim 43 wherein said polypeptide is further characterized by comprising the amino acid sequence ETLRQCFDDFADLVPFDSWEPLMRKLGLMDNEIKVAKAEAAGHRDTLXTML (SEQ ID NO:4).

46. The antibody or antigen-binding fragment of claim 38, wherein the antibody is a monoclonal antibody.

47. The antibody or antigen-binding fragment of claim 40, wherein the antibody is a monoclonal antibody.

48. The antibody or antigen-binding fragment of claim 41, wherein the antibody is a monoclonal antibody.

49. The antibody or antigen-binding fragment of claim 42, wherein the antibody is a monoclonal antibody.

Supplemental Amendment
Docket No. 2625-E

Immunex Corporation

50. The antibody or antigen-binding fragment of claim 43, wherein the antibody is a monoclonal antibody.

51. The antibody or antigen-binding fragment of claim 44, wherein the antibody is a monoclonal antibody.

52. The antibody or antigen-binding fragment of claim 45, wherein the antibody is a monoclonal antibody.

53. The antibody or antigen-binding fragment of claim 38, wherein the antibody is a humanized antibody.

54. The antibody or antigen-binding fragment of claim 40, wherein the antibody is a humanized antibody.

55. The antibody or antigen-binding fragment of claim 41, wherein the antibody is a humanized antibody.

56. The antibody or antigen-binding fragment of claim 42, wherein the antibody is a humanized antibody.

57. The antibody or antigen-binding fragment of claim 43, wherein the antibody is a humanized antibody.

58. The antibody or antigen-binding fragment of claim 44, wherein the antibody is a humanized antibody.

59. The antibody or antigen-binding fragment of claim 45, wherein the antibody is a humanized antibody.

60. A composition comprising the antibody or antigen-binding fragment of claim 38 and a physiologically acceptable diluent, excipient, or carrier.

61. A composition comprising the antibody or antigen-binding fragment of claim 40 and a physiologically acceptable diluent, excipient, or carrier.

62. A composition comprising the antibody or antigen-binding fragment of claim 41 and a physiologically acceptable diluent, excipient, or carrier.

63. A composition comprising the antibody or antigen-binding fragment of claim 42 and a physiologically acceptable diluent, excipient, or carrier.

64. A composition comprising the antibody or antigen-binding fragment of claim 43 and a physiologically acceptable diluent, excipient, or carrier.

Supplemental Amendment
Docket No. 2625-E

Immunex Corporation

65. A composition comprising the antibody or antigen-binding fragment of claim 44 and a physiologically acceptable diluent, excipient, or carrier.

66. A composition comprising the antibody or antigen-binding fragment of claim 45 and a physiologically acceptable diluent, excipient, or carrier.

67. A conjugate comprising a detectable or therapeutic agent attached to the antibody or antigen-binding fragment of claim 38.

68. A conjugate comprising a detectable or therapeutic agent attached to the antibody or antigen-binding fragment of claim 40.

69. A conjugate comprising a detectable or therapeutic agent attached to the antibody or antigen-binding fragment of claim 41.

70. A conjugate comprising a detectable or therapeutic agent attached to the antibody or antigen-binding fragment of claim 42.

71. A conjugate comprising a detectable or therapeutic agent attached to the antibody or antigen-binding fragment of claim 43.

72. A conjugate comprising a detectable or therapeutic agent attached to the antibody or antigen-binding fragment of claim 44.

73. A conjugate comprising a detectable or therapeutic agent attached to the antibody or antigen-binding fragment of claim 45.

C2 74. (New) The antibody or antigen binding fragment of claim 38, wherein the antibody or antigen binding fragment blocks binding of TRAIL-R to TRAIL.

75. (New) The antibody or antigen binding fragment of claim 40, wherein the antibody or antigen binding fragment blocks binding of TRAIL-R to TRAIL.

76. (New) The antibody or antigen binding fragment of claim 41, wherein the antibody or antigen binding fragment blocks binding of TRAIL-R to TRAIL.

77. (New) The antibody or antigen binding fragment of claim 42, wherein the antibody or antigen binding fragment blocks binding of TRAIL-R to TRAIL.

78. (New) The antibody or antigen binding fragment of claim 43, wherein the antibody or antigen binding fragment blocks binding of TRAIL-R to TRAIL.

79. (New) The antibody or antigen binding fragment of claim 44, wherein the antibody or antigen binding fragment blocks binding of TRAIL-R to TRAIL.